Abstracts
3427229
(#58) Real-World Persistence on Olanzapine/Samidorphan Versus Other Oral Second-Generation Antipsychotics in Patients With Schizophrenia
Abstract: Introduction: Poor persistence/adherence to oral antipsychotics is common and associated with increased relapse risk. This study evaluated real-world persistence/adherence with OLZ/SAM vs other oral second-generation antipsychotics (SGAs) among patients with schizophrenia.
Methods: This retrospective claims analysis used Komodo Healthcare Map data (10/18/2020-12/31/2024). Medicaid-insured adults with schizophrenia and ≥1 claim for OLZ/SAM or a comparator SGA were included. Cohorts were balanced on key demographic/clinical variables. Proportions of patients persisting on the same medication as on the index date for the full study period, durations of persistence, and adherence (medication possession ratio [MPR] ≥0.80) were compared for OLZ/SAM vs comparator oral SGA cohorts during 12-month follow-up.
Results: Overall, 45,566 patients with schizophrenia were included (OLZ/SAM, n=1244; aripiprazole, n=11,995; brexpiprazole, n=421; cariprazine, n=1650; lumateperone, n=423; lurasidone, n=2030; olanzapine, n=14,630; risperidone, n=13,173). Brexpiprazole and lumateperone were not assessed due to low numbers of patient claims. Patients initiating OLZ/SAM vs other oral SGAs were significantly more likely to remain on treatment at 12 months (odds ratio [OR] range, 1.57-2.71; all P 0.001). Mean (SD) duration of persistence was significantly longer with OLZ/SAM (201.8±143.6 days) vs all comparators (range, 132.1±129.5 to 174.1±138.8 days; all P 0.001). Patients initiating OLZ/SAM were twice as likely to be adherent (MPR ≥ 0.80 OR range, 1.33-2.53; all P 0.001).
Conclusions: OLZ/SAM was associated with a significantly higher proportion of patients persistent on treatment, longer duration of persistence, and greater adherence during 12-month follow-up vs all comparator oral SGAs. More consistent antipsychotic medication use may translate into meaningful improvements in schizophrenia-associated outcomes.
Short Description: This retrospective analysis of Medicaid claims compared persistence/adherence among adults with schizophrenia initiating combined olanzapine/samidorphan (OLZ/SAM) vs other oral second-generation antipsychotics (aripiprazole, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, or risperidone). Patients initiating OLZ/SAM were significantly more likely to remain on treatment over 12 months, were persistent longer, and were nearly twice as likely to be adherent vs those initiating a comparator. These findings suggest that more consistent antipsychotic medication use may translate into improved schizophrenia-associated outcomes.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
Methods: This retrospective claims analysis used Komodo Healthcare Map data (10/18/2020-12/31/2024). Medicaid-insured adults with schizophrenia and ≥1 claim for OLZ/SAM or a comparator SGA were included. Cohorts were balanced on key demographic/clinical variables. Proportions of patients persisting on the same medication as on the index date for the full study period, durations of persistence, and adherence (medication possession ratio [MPR] ≥0.80) were compared for OLZ/SAM vs comparator oral SGA cohorts during 12-month follow-up.
Results: Overall, 45,566 patients with schizophrenia were included (OLZ/SAM, n=1244; aripiprazole, n=11,995; brexpiprazole, n=421; cariprazine, n=1650; lumateperone, n=423; lurasidone, n=2030; olanzapine, n=14,630; risperidone, n=13,173). Brexpiprazole and lumateperone were not assessed due to low numbers of patient claims. Patients initiating OLZ/SAM vs other oral SGAs were significantly more likely to remain on treatment at 12 months (odds ratio [OR] range, 1.57-2.71; all P 0.001). Mean (SD) duration of persistence was significantly longer with OLZ/SAM (201.8±143.6 days) vs all comparators (range, 132.1±129.5 to 174.1±138.8 days; all P 0.001). Patients initiating OLZ/SAM were twice as likely to be adherent (MPR ≥ 0.80 OR range, 1.33-2.53; all P 0.001).
Conclusions: OLZ/SAM was associated with a significantly higher proportion of patients persistent on treatment, longer duration of persistence, and greater adherence during 12-month follow-up vs all comparator oral SGAs. More consistent antipsychotic medication use may translate into meaningful improvements in schizophrenia-associated outcomes.
Short Description: This retrospective analysis of Medicaid claims compared persistence/adherence among adults with schizophrenia initiating combined olanzapine/samidorphan (OLZ/SAM) vs other oral second-generation antipsychotics (aripiprazole, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, or risperidone). Patients initiating OLZ/SAM were significantly more likely to remain on treatment over 12 months, were persistent longer, and were nearly twice as likely to be adherent vs those initiating a comparator. These findings suggest that more consistent antipsychotic medication use may translate into improved schizophrenia-associated outcomes.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
